株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界の尋常性天疱瘡市場の予測

Global Pemphigus Vulgaris Market Research Report Forecast to 2027

発行 Market Research Future 商品コード 830806
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
世界の尋常性天疱瘡市場の予測 Global Pemphigus Vulgaris Market Research Report Forecast to 2027
出版日: 2019年03月01日 ページ情報: 英文 95 Pages
概要

当レポートでは、世界の尋常性天疱瘡市場について調査分析を行い、市場概要、市場動向、市場促進因子/抑制因子などについて考察するとともに、治療別、投与経路別、エンドユーザー別、地域別に市場を分析、主要企業のプロファイルなどについて包括的に分析し、まとめています。

第1章 序章

第2章 市場のイントロダクション

第3章 調査方法

第4章 市場のダイナミクス

  • イントロダクション
  • 促進因子
  • 抑制因子
  • 機会
  • 課題

第5章 市場因子分析

  • 概要
  • ファイブフォース分析
  • 代替品の驚異
  • 競合度
  • 投資機会分析

第6章 世界の尋常性天疱瘡市場:治療別

  • イントロダクション
  • コルチコステロイド剤
  • 免疫抑制剤
  • 生物学的療法
  • 免疫グロブリン静脈内投与 (IVIG)

第7章 世界の尋常性天疱瘡市場:投与経路別

  • イントロダクション
  • 静脈投与
  • 皮下投与
  • 経口投与

第8章 世界の尋常性天疱瘡市場:エンドユーザー別

  • イントロダクション
  • 病院/診療所
  • 癌専門クリニック
  • 学術研究ラボ

第9章 世界の尋常性天疱瘡市場:地域別

  • イントロダクション
  • 南北アメリカ
  • 欧州
  • アジア太平洋地域
  • 世界のその他の諸国

第10章 競合状況

第11章 企業プロファイル

  • Almirall, S.A
  • Argenx SE
  • Biogen Inc.
  • F. Hoffmann-La Roche
  • Syntimmune
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Janssen Global Services, LLC
  • Principia Biopharma

第12章 付録

図表

List of Tables

  • TABLE 1 LIST OF ASSUMPTIONS
  • TABLE 2 PRIMARY INTERVIEWS
  • TABLE 3 GLOBAL PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 4 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR CORTICOSTEROIDS 2015-2027 (USD MILLION)
  • TABLE 5 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR IMMUNOSUPPRESSANTS 2015-2027 (USD MILLION)
  • TABLE 6 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR BIOLOGICAL THERAPIES 2015-2027 (USD MILLION)
  • TABLE 7 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR INTRAVENOUS IMMUNOGLOBULIN (IVIG) THERAPY 2015-2027 (USD MILLION)
  • TABLE 8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 9 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR INTRAVENOUS 2015-2027 (USD MILLION)
  • TABLE 10 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR SUBCUTANEOUS 2015-2027 (USD MILLION)
  • TABLE 11 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR ORAL 2015-2027 (USD MILLION)
  • TABLE 12 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END-USER 2015-2027 (USD MILLION)
  • TABLE 13 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR HOSPITALS & CLINICS 2015-2027 (USD MILLION)
  • TABLE 14 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR SPECIALTY DERMATOLOGY CLINICS 2015-2027 (USD MILLION)
  • TABLE 15 GLOBAL PEMPHIGUS VULGARIS MARKET, FOR RESEARCH & ACADEMIC LABORATORIES 2015-2027 (USD MILLION)
  • TABLE 16 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION 2015-2027 (USD MILLION)
  • TABLE 17 AMERICAS PEMPHIGUS VULGARIS MARKET, BY REGION 2015-2027 (USD MILLION)
  • TABLE 18 AMERICAS PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 19 AMERICAS PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 20 AMERICAS PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 21 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY 2015-2027 (USD MILLION)
  • TABLE 22 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 23 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 24 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 25 U.S PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 26 U.S PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 27 U.S PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 28 CANADA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 29 CANADA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 30 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 31 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 32 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 33 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 34 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION 2015-2027 (USD MILLION)
  • TABLE 35 EUROPE PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 36 EUROPE PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 37 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 38 WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY 2015-2027 (USD MILLION)
  • TABLE 39 WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 40 WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 41 WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 42 GERMANY PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 43 GERMANY PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 44 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 45 U.K PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 46 U.K PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 47 U.K PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 48 FRANCE PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 49 FRANCE PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 50 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 51 ITALY PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 52 ITALY PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 53 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 54 SPAIN PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 55 SPAIN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 56 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 57 REST OF WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 58 REST OF WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 59 REST OF WESTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 60 EASTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 61 EASTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 62 EASTERN EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 63 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY/REGION 2015-2027 (USD MILLION)
  • TABLE 64 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 65 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 66 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 67 JAPAN PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 68 JAPAN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 69 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 70 CHINA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 71 CHINA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 72 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 73 INDIA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 74 INDIA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 75 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 76 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 77 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 78 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 79 REPUBLIC OF KOREA PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 80 REPUBLIC OF KOREA PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 81 REPUBLIC OF KOREA PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 82 REST OF ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 83 REST OF ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 84 REST OF ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)
  • TABLE 85 REST OF THE WORLD PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2015-2027 (USD MILLION)
  • TABLE 86 REST OF THE WORLD PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2015-2027 (USD MILLION)
  • TABLE 87 REST OF THE WORLD PEMPHIGUS VULGARIS MARKET, BY END USER 2015-2027 (USD MILLION)

List of Figures

  • FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: MARKET STRUCTURE
  • FIGURE 2 RESEARCH PROCESS
  • FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 4 SUPPLY CHAIN: GLOBAL PEMPHIGUS VULGARIS MARKET
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEMPHIGUS VULGARIS MARKET
  • FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET, BY TREATMENT 2017 & 2027 (USD MILLION)
  • FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION 2017 & 2027 (USD MILLION)
  • FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END-USER 2017 & 2027 (USD MILLION)
  • FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2017 (%)
  • FIGURE 10 AMERICAS PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2017 (%)
  • FIGURE 11 NORTH AMERICA PEMPHIGUS VULGARIS MARKET SAHRE, BY COUNTRY 2017 (%)
  • FIGURE 12 EUROPE PEMPHIGUS VULGARIS MARKET SHARE, BY REGION 2017 (%)
  • FIGURE 13 WESTERN EUROPE PEMPHIGUS VULGARIS MARKET SAHRE, BY CONTRY 2017 (%)
  • FIGURE 14 ASIA PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY/REGION 2017 (%)
  • FIGURE 15 TOP PLAYERS IN THE GLOBAL PEMPHIGUS VULGARIS MARKET
目次

A pemphigus vulgaris is a type of autoimmune disease in which the antibodies produced against the bacteria attack the normal cells and causes skin problems. Pemphigus vulgaris equally affects man and woman but middle and old age people are more prone to develop this condition. The major factors responsible for influencing the market growth are the increasing prevalence of pemphigus vulgaris, rising bacterial and viral infection, increasing geriatric population, and growing financial support by several private and public organizations for the research of chronic skin diseases. According to the International Pemphigus & Pemphigoid Foundation, it was predicted that approximately 40,000 to 50,000 people across the world and 2,500 people in the US had pemphigus disorder in 2017. On the other hand, factors such as high cost related to treatment, unfavorable reimbursement situation, and lack of awareness are expected to restrain the market growth.

The global pemphigus vulgaris market has been segmented based on treatment, route of administration, end user, and region.

Based on treatment, the market has been segmented into corticosteroids, immunosuppressants, biological therapies, and intravenous immunoglobulin (IVIG) therapy.

Based on route of administration, the market has been segmented into intravenous, subcutaneous, and oral.

Based on end user, the market has been segmented into hospitals and clinics, specialty dermatology clinics, and research and academic laboratories.

The global pemphigus vulgaris market is expected to register a CAGR of 8.0% during the forecast period of 2018 to 2027.

Key Players

Almirall, S.A, Argenx SE, Biogen Inc., F. Hoffmann-La Roche, Syntimmune, Pfizer Inc., Novartis AG, Sanofi, Janssen Global Services, LLC, Principia Biopharma, and others.

Study Objectives

  • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the global pemphigus vulgaris market
  • To provide insights into factors affecting the market growth
  • To analyze the pemphigus vulgaris market based on various tools such as supply chain analysis and Porter's five force analysis
  • To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
  • To provide country-level analysis of the market with respect to the current market size and future perspective
  • To provide country-level analysis of the market for segments by product, type, end user, and region
  • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pemphigus vulgaris market

Target Audience

  • Pharmaceutical and biotechnology companies
  • Hospitals & clinics
  • Academic research institutes
  • Government institutes

Key Findings

  • The global pemphigus vulgaris market is expected to register a CAGR of 8.0% during the forecast period of 2018-2027
  • Based on treatment, the corticosteroids segment accounted for the largest market share of 28.6% in 2017, with a market value of USD 82.60 million
  • Based on route of administration, the oral segment accounted for the largest market share of 26.6% in 2017, with a market value of USD 77.08 million
  • Based on end user, the hospitals and clinics segment accounted for the largest market share in 2017, with a market value of USD 129.70 million
  • The Americas holds the largest share of the global pemphigus vulgaris market which is expected to reach USD 297.41 million by 2027
  • Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 8.2% over 2018 to 2027

Regional Analysis

  • Americas
    • North America
  • US
  • Canada
    • South America
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Middle East
    • Africa

Table of Contents

1 Report Prologue

2 Market Introduction

  • 2.1 Scope of Study
  • 2.2 Research Objective
  • 2.3 List of Assumptions

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation

4 Market Dynamics

  • 4.1 Introduction
  • 4.2 Drivers
    • 4.2.1 Increasing prevalence of pemphigus vulgaris globally
    • 4.2.2 Growing financial support by various private and government organizations for research of diseases
    • 4.2.3 Increasing geriatric population
  • 4.3 Restraints
    • 4.3.1 Lack of awareness among the countries
    • 4.3.2 High cost of treatment
  • 4.4 Opportunities
    • 4.4.1 Advancements in treatments
  • 4.5 Challenge
    • 4.5.1 Adverse side-effects of the treatment

5 Market Factor Analysis

  • 5.1 Overview
    • 5.1.1 R&D
    • 5.1.2 Manufacturing
    • 5.1.3 Distribution & Sales
    • 5.1.4 Post-Sales Monitoring
  • 5.2 Porter's Five Forces Model
    • 5.2.1 Overview
    • 5.2.2 Bargaining Power of Suppliers
    • 5.2.3 Bargaining Power of Buyers
    • 5.2.4 Threat of New Entrants
  • 5.3 Threat of Substitutes
  • 5.4 Intensity of Rivalry
  • 5.5 Investment Opportunity Analysis

6 Global Pemphigus Vulgaris Market, By Treatment

  • 6.1 Introduction
  • 6.2 Corticosteroids
  • 6.3 Immunosuppressants
  • 6.4 Biological Therapies
  • 6.5 Intravenous Immunoglobulin (IVIG) Therapy

7 Global Pemphigus Vulgaris Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous
  • 7.3 Subcutaneous
  • 7.4 Oral

8 Global Pemphigus Vulgaris Market, By End-user

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Specialty Dermatology Clinics
  • 8.4 Research & Academic Laboratories

9 Global Pemphigus Vulgaris Market, By Region

  • 9.1 Introduction
  • 9.2 Americas
    • 9.2.1 North America
      • 9.2.1.1 U.S
      • 9.2.1.2 Canada
    • 9.2.2 South America
  • 9.3 Europe
    • 9.3.1 Western Europe
      • 9.3.1.1 Germany
      • 9.3.1.2 U.K
      • 9.3.1.3 France
      • 9.3.1.4 Italy
      • 9.3.1.5 Spain
      • 9.3.1.6 Rest of Western Europe
    • 9.3.2 Eastern Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 Republic of Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Rest of the World

10 Competitive Landscape

  • 10.1 Introduction

11 Company Profiles

  • 11.1 Almirall, S.A
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategy
  • 11.2 Argenx SE
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategy
  • 11.3 Biogen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offered
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategy
  • 11.4 F. Hoffmann-La Roche
    • 11.4.1 Company Overview
    • 11.4.2 Financial Overview
    • 11.4.3 Products/Services Offered
    • 11.4.4 SWOT Analysis
    • 11.4.5 Key Strategy
  • 11.5 Syntimmune
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategy
  • 11.6 Pfizer Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Financial Overview
    • 11.6.3 Products/Services Offered
    • 11.6.4 Key Developments
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Strategy
  • 11.7 Novartis AG
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategy
  • 11.8 Sanofi
    • 11.8.1 Company Overview
    • 11.8.2 Financial Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 Key Developments
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Strategy
  • 11.9 Janssen Global Services, LLC
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategy
  • 11.1 Principia Biopharma
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategy

12 Appendix

  • 12.1 Discussion Blue Print
Back to Top